Antimicrobial resistance and susceptibility testing of anaerobic bacteria

Clinical Infectious Diseases

Volumn 59, Issue 5, 2014, Pages 698-705

  Schuetz, Audrey N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anaerobe; Anaerobic bacteria; Resistance; Susceptibility; Susceptibility test methods

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM; CARBAPENEM DERIVATIVE; CEFOXITIN; CEPHALOSPORIN; CLAVULANIC ACID; CLINDAMYCIN; DALBAVANCIN; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; FIDAXOMICIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAXIMIN; TELAVANCIN; TETRACYCLINE; TICARCILLIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGAR DILUTION; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEROIDES FRAGILIS; BROTH DILUTION; DIFFUSION; DISK DIFFUSION; ENDOSPORE-FORMING RODS AND COCCI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; MINIMUM INHIBITORY CONCENTRATION GRADIENT DIFFUSION METHOD; NONHUMAN; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; DRUG EFFECTS; LABORATORY; MICROBIAL SENSITIVITY TEST; PROCEDURES; STANDARDS;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; DRUG RESISTANCE, MICROBIAL; LABORATORIES; MICROBIAL SENSITIVITY TESTS;

EID: 84907401612     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu395     Document Type: Article

References (54)

1. Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin Infect Dis 2007; 44:895-900. (Pubitemid 46452050)
2. Goldstein EJ, Solomkin JS, Citron DM, Alder JD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis 2011; 53:1074-80.
3. Nagy E, Urbán E, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011; 17:371-9.
4. Snydman DR, Jacobus NV, McDermott LA, et al. Lessons learned from the anaerobe survey: Historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010; 50:S26-33.
5. Roberts SA, Shore KP, Paviour SD, Holland D, Morris AJ. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003. J Antimicrob Chemother 2006; 57:992-8.
6. Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother 2012; 56:1247-52.
7. Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000; 30:870-6. (Pubitemid 32250323)
8. Aldridge KE, Ashcraft D, O'Brien M, Sanders CV. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2003; 47:148-53. (Pubitemid 36070356)
9. Boente RF, Ferreira LQ, Falcão LS, et al. Detection of resistance genes and susceptibility patterns in Bacteroides and Parabacteroides strains. Anaerobe 2010; 16:190-4.
10. Piriz S, Vadillo S, Quesada A, Criado J, Cerrato R, Ayala J. Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol 2004; 53:213-21. (Pubitemid 38340120)
11. Treviño M, Areses P, Peñalver MD, et al. Susceptibility trends of Bacteroides fragilis group and characterization of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. Anaerobe 2012; 18:37-43.
12. Snydman DR, Jacobus NV, McDermott LA, et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 2011; 17:147-51.
13. Seifert H, Dalhoff A; PRISMA Study Group. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 2010; 65:2405-10.
14. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013; 26:526-46.
15. Sherwood JE, Fraser S, Citron DM, et al. Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe 2011; 17:152-5.
16. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 11:79-109.
17. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999; 43:2823-30.
18. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008; 52:3161-8.
19. Gal M, Brazier JS. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother 2004; 54:109-16. (Pubitemid 39028976)
20. Goldstein EJ, Citron DM, Goldman PJ, Goldman RJ. National hospital survey of anaerobic culture and susceptibility methods: III. Anaerobe 2008; 14:68-72.
21. Bahar H, Torun MM, Demirci M, Kocazeybek B. Antimicrobial resistance and beta-lactamase production of clinical isolates of Prevotella and Porphyromonas species. Chemotherapy 2005; 51:9-14. (Pubitemid 41201967)
22. Kononen E, Wade WG, Citron DM. Bacteroides, Porphyromonas, Prevotella, Fusobacterium, and other anaerobic gram-negative rods. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW. Manual of clinical microbiology. Vol 1. 10th ed. Washington, DC: ASM Press, 2011:858-80.
23. Wybo I, Van den Bossche D, Soetens O, et al. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2014; 69:155-61.
24. Koeth LM, Good CE, Appelbaum PC, et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 2004; 53:1039-44. (Pubitemid 38807646)
25. Oprica C, Nord CE. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 2005; 11:204-13. (Pubitemid 40352767)
26. Tyrrell KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 2006; 50:2728-31. (Pubitemid 44198694)
27. Wade WG, Kononen K. Propionibacterium, Lactobacillus, Actinomyces, and other non-spore-forming anaerobic gram-positive rods. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW. Manual of clinical microbiology. Vol 1. 10th ed. Washington, DC: ASM Press, 2011:817-33.
28. Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes: microbiological and clinical aspects. Anaerobe 2006; 12:207-10. (Pubitemid 44666468)
29. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006; 42:e35-44.
30. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium species Antimicrob Agents Chemother 2004; 48:2149-52. (Pubitemid 38691612)
31. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003; 47:2334-8. (Pubitemid 36753596)
32. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli. Antimicrob Agents Chemother 2005; 49:408-13.
33. Leal J, Gregson DB, Ross T, Church DL, Laupland KB. Epidemiology of Clostridium species bacteremia in Calgary, Canada, 2000-2006. J Infect 2008; 57:198-203.
34. Johansson A, Greko C, Engström BE, Karlsson M. Antimicrobial susceptibility of Swedish, Norwegian and Danish isolates of Clostridium perfringens from poultry, and distribution of tetracycline resistance genes. Vet Microbiol 2004; 99:251-7. (Pubitemid 38471658)
35. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 2006; 12:115-21. (Pubitemid 43831678)
36. Stevens DL, Bryant AE, Berger A, von Eichel-Streiber C. Clostridium. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW. Manual of clinical microbiology. Vol 1. 10th ed. Washington, DC: ASM Press; 2011: 834-57.
37. Hawser SP. Activity of tigecycline against multidrug-resistant clinical isolates of Clostridium spp.: from Europe. Int J Antimicrob Agents 2010; 35:310-1.
38. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51:2716-9. (Pubitemid 47206204)
39. Labbé AC, Poirier L, Maccannell D, et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 2008; 52:3180-7.
40. Kunishima H, Chiba J, Saito M, Honda Y, Kaku M. Antimicrobial susceptibilities of Clostridium difficile isolated in Japan. J Infect Chemother 2013; 19:360-2.
41. Spigaglia P, Barbanti F, Mastrantonio P; European Study Group on Clostridium difficile (ESGCD). Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 2011; 66:2227-34.
42. Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 2014; 69:41-4.
43. Nagy E. Anaerobic infections: update on treatment considerations. Drugs 2010; 70:841-58.
44. Veloo AC, Welling GW, Degener JE. Antimicrobial susceptibility of clinically relevant gram-positive anaerobic cocci collected over a three-year period in the Netherlands. Antimicrob Agents Chemother 2011; 55:1199-203.
45. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 8th ed. CLSI document M11-A8. Wayne, PA: CLSI, 2012.
46. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Wayne, PA: CLSI, 2013.
47. European Committee on Antimicrobial Susceptibility Testing, EUCAST. Clinical breakpoints for bacteria. Available at: http://www.eucast.org/clinical- breakpoints/. Accessed 6 June 2014.
48. Toprak NU, Uzunkaya OD, Sóki J, Soyletir G. Susceptibility profiles and resistance genes for carbapenems (cfiA) and metronidazole (nim) among Bacteroides species in a Turkish University Hospital. Anaerobe 2012; 18:169-71.
49. Cormican MG, Erwin ME, Jones RN. False resistance tometronidazole by E-test among anaerobic bacteria investigations of contributing test conditions and medium quality. Diagn Microbiol Infect Dis 1996; 24:117-9.
50. Sensititre TREK Diagnostic Systems Anaerobe MIC Plate. Thermo Fisher Scientific. Available at: http://www.trekds.com/products/sensititre/c-anaerobe. asp. Accessed 6 June 2014.
51. Thermo Scientific Oxoid ANA MIC Panels. Available at: http://www.thermoscientific.com/ecomm/servlet/productsdetail?productId= 15648363&groupType=PRODUCT&searchType=0&storeId=11152&from= search. Accessed 6 June 2014.
52. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007; 20:593-621. (Pubitemid 47623770)
53. Summanen P. Identification by using special-potency disks, p 4.6.5.1-4.6.5.2. In: Garcia LS, ed. Clinical microbiology procedures handbook. 3rd ed. Vol 1. Washington, DC: ASM Press, 2010.
54. Clinical and Laboratory Standards Institute. Analysis and presentation of cumulative antimicrobial susceptibility testing data; approved guideline. 3rd ed. CLSI document M39-A3. Wayne, PA: CLSI, 2008.